Review article: liver support systems in acute hepatic failure.

abstract：:The Consensus Conference on Hepatorenal Syndrome (HRS) organized by the International Ascites Club in 1994 redefined HRS, introduced new diagnostic criteria that are now widely accepted, and proposed the distinction between two types of HRS: type 1 and type 2. Before the introduction of the new therapeutic options, th...

journal_title：Alimentary pharmacology & therapeutics

authors： Angeli P

更新日期：2004-09-01 00:00:00

abstract：:Suppositories containing 300 mg 5-aminosalicylic acid (1.96 mmol) or 425 mg acetyl-5-aminosalicylic acid (1.96 mmol) were used in 40 patients with idiopathic proctitis to determine the efficacy of acetyl-5-aminosalicylic acid in treating this bowel inflammation. Each patient was treated with 5-aminosalicylic acid or a...

journal_title：Alimentary pharmacology & therapeutics

authors： van Hogezand RA,van Hees PA,van Gorp JP,van Lier HJ,Bakker JH,Wesseling P,van Haelst UJ,van Tongeren JH

更新日期：1988-02-01 00:00:00

abstract：AIM:To investigate the incidence of death in patients diagnosed with Crohn's disease in Cardiff over 20 years ago. METHODS:The Cardiff database of patients with Crohn's disease contains data on all patients diagnosed there since 1934. Patients (394) diagnosed before 1 January 1985 were traced and their mortality statu...

journal_title：Alimentary pharmacology & therapeutics

authors： Canavan C,Abrams KR,Hawthorne B,Mayberry JF

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Adalimumab is effective in inducing remission in patients with active Crohn's disease who had secondary failure to infliximab therapy. AIM:To evaluate the efficacy and safety of adalimumab maintenance therapy in Crohn's disease patients who previously responded to infliximab and then lost response or became...

journal_title：Alimentary pharmacology & therapeutics

authors： Peyrin-Biroulet L,Laclotte C,Bigard MA

更新日期：2007-03-15 00:00:00

abstract：BACKGROUND:Long-acting somatostatin analogues have been suggested as an alternative to propranolol for the prevention of variceal rebleeding. AIM:To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulate...

journal_title：Alimentary pharmacology & therapeutics

authors： Schiedermaier P,Koch L,Stoffel-Wagner B,Layer G,Sauerbruch T

更新日期：2003-10-15 00:00:00

abstract：BACKGROUND:4-Aminosalicylic acid has the potential for use in the treatment of diseases of the colon. AIM:To assess the feasibility of delivering 4-aminosalicylic acid directly to the colon using a hydroxypropylmethylcellulose capsule coated with a mixture of amylose, a polysaccharide metabolized by bacterial enzymes ...

journal_title：Alimentary pharmacology & therapeutics

authors： Tuleu C,Basit AW,Waddington WA,Ell PJ,Newton JM

更新日期：2002-10-01 00:00:00

abstract：BACKGROUND:Ursodeoxycholic acid (UDCA) prolongs transplantation-free survival in primary biliary cirrhosis (PBC). However, the optimal therapeutic dose has not been established. AIM:To compare the effects of UDCA administered in daily doses of 10 vs. 20 mg/kg on symptoms, liver biochemistry and biliary UDCA enrichment...

journal_title：Alimentary pharmacology & therapeutics

authors： Van Hoogstraten HJ,De Smet MB,Renooij W,Breed JG,Engels LG,Den Ouden-Muller JW,Rijk MC,Smit AM,Zwertbroek R,Hop WC,van Berge Henegouwen GP,Schalm SW,van Buuren HR

更新日期：1998-10-01 00:00:00

abstract：BACKGROUND:Diagnosis and management of chronic antibiotic-refractory pouchitis and Crohn's disease of the pouch can be challenging. Pyloric gland metaplasia is a histological feature indicative of chronic mucosal inflammation. Its value in diagnosis and prognosis of pouch disorders has not been investigated. AIM:To as...

journal_title：Alimentary pharmacology & therapeutics

authors： Kariv R,Plesec TP,Gaffney K,Lian L,Fazio VW,Remzi FH,Lopez R,Goldblum JR,Shen B

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). AIM:A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, ...

journal_title：Alimentary pharmacology & therapeutics

authors： Quigley EM,Vandeplassche L,Kerstens R,Ausma J

更新日期：2009-02-01 00:00:00

abstract：:Visceral hypersensitivity is highly prevalent in all functional bowel disorders. Most also demonstrate wider patterns of somatic referral of intestinal pain or discomfort. This hypersensitivity may explain the symptoms as the sensitive gut can be more easily provoked by normal or abnormal motor events in the gut. Visc...

journal_title：Alimentary pharmacology & therapeutics

authors： Mertz H

更新日期：2003-03-01 00:00:00

abstract：BACKGROUND:Ranitidine 75 mg (Zantac 75) has been shown to be effective for the treatment of pre-existing heartburn symptoms. AIM:To compare the efficacy of dosing ranitidine 75 mg or placebo 30 min prior to a proven heartburn-provoking meal in completely preventing or reducing subsequent heartburn symptoms. METHODS:A...

journal_title：Alimentary pharmacology & therapeutics

authors： Pappa KA,Williams BO,Payne JE,Buaron KS,Mussari KL,Ciociola AA

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. AIM:To evaluate the effects of UDCA administration on acute viral hepatitis-related cholestasis and the course of acute viral hepatitis. METHO...

journal_title：Alimentary pharmacology & therapeutics

authors： Fabris P,Tositti G,Mazzella G,Zanetti AR,Nicolin R,Pellizzer G,Benedetti P,de Lalla F

更新日期：1999-09-01 00:00:00

abstract：:Thirteen patients with Zollinger-Ellison syndrome were investigated: 8 without, and 5 with, previous gastric surgery. After 7-34 months of treatment with famotidine, 8 out of 13 patients were resistant to this drug. Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 ...

journal_title：Alimentary pharmacology & therapeutics

authors： Corleto V,Annibale B,D'Ambra G,Saggioro A,Ferrua B,Cassetta MR,Delle Fave G

更新日期：1993-04-01 00:00:00

abstract：BACKGROUND:Substance P acting via the neurokinin-1 receptor is involved in the development of hyperalgesia, although studies using neurokinin-1 receptor antagonists (NK-1RA) in human somatic pain have been disappointing. AIM:To evaluate whether Substance P is involved in the development of human visceral pain/hyperalg...

journal_title：Alimentary pharmacology & therapeutics

authors： Willert RP,Hobson AR,Delaney C,Hicks KJ,Dewit OE,Aziz Q

更新日期：2007-02-01 00:00:00

abstract：:In a double-blind, placebo-controlled study of SK&F 94482 (BMY-25368) (400-mg, post-evening meal, for 7 days in 11 healthy subjects), there was a significant 75% decrease in median integrated 24-h intragastric acidity during dosing with the drug (218 mmol h/L) compared with placebo (883 mmol h/L; P = 0.003). The singl...

journal_title：Alimentary pharmacology & therapeutics

authors： Gavey CJ,Smith JT,Nwokolo CU,Pounder RE

更新日期：1989-12-01 00:00:00

abstract：BACKGROUND:Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies. AIMS:To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FD...

journal_title：Alimentary pharmacology & therapeutics

authors： Dulai PS,Jairath V,Khanna R,Ma C,McCarrier KP,Martin ML,Parker CE,Morris J,Feagan BG,Sandborn WJ

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:Furazolidone-based regimens for the eradication of Helicobacter pylori are low cost and effective. Unfortunately, the usual dose of furazolidone is not tolerable in many patients. Lower doses of furazolidone are expected to cause fewer adverse effects. AIM:To investigate the efficacy of low-dose furazolidon...

journal_title：Alimentary pharmacology & therapeutics

authors： Fakheri H,Merat S,Hosseini V,Malekzadeh R

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Epidemiological studies of microscopic colitis have shown varying but increasing incidence rates. AIM:To assess the incidence of microscopic colitis in Sweden. METHODS:Nationwide cohort study performed in 1995-2015 based on biopsy reports. Age-specific and age-standardised incidence rates were calculated. ...

journal_title：Alimentary pharmacology & therapeutics

authors： Bergman D,Clements MS,Khalili H,Agréus L,Hultcrantz R,Ludvigsson JF

更新日期：2019-06-01 00:00:00

abstract：BACKGROUND:Controversy exists on how to measure patient-reported outcomes in irritable bowel syndrome (IBS) clinical trials effectively. Pain numeric rating scales (NRS) are widely used in the non-IBS pain literature. The Food and Drug Administration has proposed using the NRS in IBS. AIM:To test the psychometrics of ...

journal_title：Alimentary pharmacology & therapeutics

authors： Spiegel B,Bolus R,Harris LA,Lucak S,Naliboff B,Esrailian E,Chey WD,Lembo A,Karsan H,Tillisch K,Talley J,Mayer E,Chang L

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:Abnormal gall-bladder motility has been reported in diabetics. The objective was to evaluate the effect of chronic D2-dopamine receptor inhibition on gall-bladder emptying in diabetic patients. METHODS:Under double-blind placebo-controlled conditions and according to a crossover design, patients were random...

journal_title：Alimentary pharmacology & therapeutics

authors： Mansi C,Savarino V,Vigneri S,Sciabà L,Perilli D,Mele MR,Celle G

更新日期：1995-04-01 00:00:00

abstract：:Irritable bowel syndrome is a disease that can be diagnosed positively on the basis of an established series of criteria and limited exclusion of organic disease. It is the most common disease diagnosed by gastroenterologists and affects about 20% of all people at any one time. Symptoms fluctuate, and the overall prev...

journal_title：Alimentary pharmacology & therapeutics

authors： Camilleri M,Choi MG

更新日期：1997-02-01 00:00:00

abstract：BACKGROUND:Pregabalin has a broad spectrum of analgesic and antihyperalgesic activity in both basic and clinical studies. However, its mechanisms and sites of action have yet to be determined in humans. AIMS:To assess the antinociceptive effect of pregabalin on experimental gut pain in patients with visceral hyperalge...

journal_title：Alimentary pharmacology & therapeutics

authors： Olesen SS,Graversen C,Olesen AE,Frøkjaer JB,Wilder-Smith O,van Goor H,Valeriani M,Drewes AM

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Non-ulcer dyspepsia is predominantly a self-managed condition, although it accounts for a significant number of general practitioner consultations and hospital referrals. Herbal medicinal products are often used for the relief of dyspeptic symptoms. AIMS:: To critically assess the evidence for and against h...

journal_title：Alimentary pharmacology & therapeutics

authors： Thompson Coon J,Ernst E

更新日期：2002-10-01 00:00:00

abstract：BACKGROUND:Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations. AIM:To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia patients. METHODS:Newly dia...

journal_title：Alimentary pharmacology & therapeutics

authors： Mikaeli J,Bishehsari F,Montazeri G,Mahdavinia M,Yaghoobi M,Darvish-Moghadam S,Farrokhi F,Shirani S,Estakhri A,Malekzadeh R

更新日期：2006-09-15 00:00:00

abstract：BACKGROUND:This randomized, double-blind, multicentre study compared lansoprazole with placebo for symptomatic relief of patients with non-erosive gastro-oesophageal reflux disease (GERD). METHODS:214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half ...

journal_title：Alimentary pharmacology & therapeutics

authors： Richter JE,Kovacs TO,Greski-Rose PA,Huang section sign B,Fisher R

更新日期：1999-06-01 00:00:00

abstract：BACKGROUND:Acute liver failure is a rare and devastating clinical condition resulting from sudden loss of hepatic parenchyma and metabolic function. The Scottish Liver Transplant Unit (SLTU) offers specialist management and emergency liver transplantation to patients with acute liver failure from across Scotland. AIM:...

journal_title：Alimentary pharmacology & therapeutics

authors： Donnelly MC,Davidson JS,Martin K,Baird A,Hayes PC,Simpson KJ

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS:To evaluate the efficacy and safety of tacrolimus in patients with IBD...

journal_title：Alimentary pharmacology & therapeutics

authors： Rodríguez-Lago I,Castro-Poceiro J,Fernández-Clotet A,Mesonero F,López-Sanromán A,López-García A,Márquez L,Clos-Parals A,Cañete F,Vicuña M,Nantes Ó,Merino O,Matallana V,Gordillo J,Elorza A,Vicente R,Casanova MJ,Ferreiro-

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Pneumatic dilation has re-emerged as a first line treatment for achalasia, but conclusions are limited by the relatively small numbers of patients studied and the lack of long term follow-up. AIM:To summarise and analyse 29 available studies evaluating pneumatic dilation for achalasia with focus on efficacy...

journal_title：Alimentary pharmacology & therapeutics

authors： Katzka DA,Castell DO

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Gastro-oesophageal reflux disease is a common entity. Erosive oesophagitis, ulcers and Barrett's oesophagus, which is found in up to 10% of gastro-oesophageal reflux disease patients, characterize severe gastro-oesophageal reflux disease. Patients with Barrett's oesophagus have 0.5% per patient-year risk of ...

journal_title：Alimentary pharmacology & therapeutics

authors： Eliakim R,Yassin K,Shlomi I,Suissa A,Eisen GM

更新日期：2004-11-15 00:00:00

abstract：BACKGROUND:Treatment with a continuous i.v. proton pump inhibitor is presumed to promote clot formation and stability by sustaining intragastric pH > or = 6. AIM:We postulated that very frequent oral dosing of proton pump inhibitors should simulate i.v. infusion and achieve similar pH control. METHODS:Twenty healthy ...

journal_title：Alimentary pharmacology & therapeutics

authors： Pais SA,Nathwani RA,Dhar V,Nowain A,Laine L

更新日期：2006-06-01 00:00:00